Corcept Therapeutics Incorporated (CORT)
Corcept Shares Rise More Than 45% in Six Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
Corcept (CORT) Upgraded to Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline
Corcept Therapeutics' strong Q2 earnings exceed expectations, with revenue climbing 39% YoY and EPS beating analyst estimates. The District Court ruled in favor of Teva, enabling the launch of a generic Korlym, which threatens Corcept's revenue. Corcept faces a lawsuit accusing it of antitrust behavior and alleged illicit bribes.
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
Corcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Truist Operator Hello.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.25 per share a year ago.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
